AstraZeneca's cancer drug fails to meet main goal in Covid-19 trials

AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalised with respiratory symptoms of Covid-19.

CORONAVIRUS SPECIAL COVERAGE ONLY ON DH

The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its Covid-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.

Coronavirus vaccine news live updates on DH

Results from the trials will not impact approved indications or pending approvals for Calquence in patients with blood cancers, the company said.